NCT05751941 2026-03-16
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
Clinical Trials
12 trialsNCT06863272 2026-03-16
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06173362 2026-03-13
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
University of California, Davis
Phase 2 Recruiting
NCT04221542 2026-03-06
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Amgen
Phase 1 Recruiting
NCT04748042 2026-03-06
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT06691984 2026-03-06
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen
Phase 3 Recruiting
NCT07287150 2026-03-05
InavoPC
Hoffmann-La Roche
Phase 2 Recruiting
NCT07230106 2026-03-03
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Recruiting
NCT07190300 2026-03-02
TulmiSTAR-02
Novartis
Phase 1/2 Recruiting
NCT06855277 2026-02-24
AcTFirst
Novartis
Phase 3 Recruiting
NCT06991556 2026-02-17
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Novartis
Phase 2 Recruiting
NCT07226986 2026-02-17
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Novartis
Phase 1/2 Recruiting